The second one, the second study, is about the assessment and management of toxic effects of cancer therapy in elderly patients. It was also a retrospective study including 120 patients all treated in the Department of Medical Oncology of Mohamed Taher Maamouri Hospital in Tunisia between June 2022 and January 2024. The aim of this study was to evaluate if a patient [??] treatment modalities and to assess the toxic effect of cancer therapy in elderly patients.

For the results the median age was about 75 years with a sex ratio of about 0.34. 73% of patients were in good general health and [??] 8% of patients had a G8 score superior to 14. 58% of tumours were classified as stage 4 and the most common cancer was colorectal cancer, it represented about 33% of our patients, followed by lung cancer in about 18% and breast cancer in about 10%. Chemotherapy was indicated in 57% of cases with adapted doses in 57%. Targeted therapy was administered for 10% and hormonal therapy alone in 10% of patients.

The most common adverse events were mild to moderate gastrointestinal toxicity observed in 69% of cases followed by haematologic toxicity in 44% of cases. Altered quality of life was observed in 20% of patients and some [??] treatment was required in 57% of cases. So dose reduction was necessary in 50% of cases and the decision to stop the treatment was made in only 3% of cases due to toxicity.

This study was a very important one for us because it tells us about the toxicity and the adverse events in our patients in Tunisia. After this study, so after this result, we started to work on ameliorating the symptoms of toxicity of the drugs. Thank you very much.